Analyst Perspective:
Germany breast cancer therapeutics market accounted for US$ XX Mn in 2022, and it is expected to grow at a CAGR of 9.5% during the period 2022 - 2030, to reach US$ XX Mn in 2030.
As per Globocan 2020, about 69,697 new instances of breast cancer were reported in 2020 in Germany, representing 11.1% of all registered cancer cases. It caused 20,579 fatalities, and the five-year prevalence rate of breast cancer in all ages was 707.38 per 100,000 population. Breast cancer treatment costs almost US$ 2.13 billion (2 billion euros) annually. According to the German Cancer Society, one in eight women will have breast cancer during their lifetime.
Numerous businesses run various programs to assist with breast cancer screenings, which can result in offering better treatment to the individual. For instance, in and around Paderborn, Germany, Radiologie am Theater has three special breast cancer diagnostic facilities. According to the center, more than 15,000 breast exams are performed annually in the country. In addition, women aged 50–69 can have a free mammogram every two years in the country. This helps detect breast cancer as early as possible to provide better treatment and increase the chances of recovery.
On the occasion of breast cancer awareness month in October, a unique campaign was initiated to shed light on the disease in October 2021. The campaign “Breast Cancer Affects Us All” has been created by Wefra Life, an advertising agency and a non-profit association Pink Ribbon Germany.
In June 2020, Vara, a Berlin-based company, aimed to save lives by making breast cancer screening accessible worldwide. It raised US$ 7.31 million (Euro 6.5 million) in a Series A funding round led by OMERS Ventures for AI-powered breast cancer screening software. Therefore, the growing disease burden is anticipated to promote the breast cancer therapeutics demand, along with its rising awareness in the country.
Market Segmentation - Breast Cancer Therapeutics Market
SEGMENT NAME | TYPE |
| Drug Therapy | Targeted Drug Therapy, Hormonal Drug Therapy, Chemotherapy, Immunotherapy/ Biological therapy |
| Targeted Drug Therapy | Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, Other Targeted Drug Therapy |
| Hormonal Drug Therapy | Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Downregulators (SERDs) |
| Breast Cancer Type | Hormone Receptor, HER2+ (human epidermal growth factor receptor 2), Triple-Negative Breast Cancer |
| Distribution Channel | Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies |
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Key Player Analysis - Breast Cancer Therapeutics Market
- Eli Lilly and Co,
- Eisai Co Ltd
- Novartis AG
- AstraZeneca Plc
- Pfizer Inc
- Gilead Sciences Inc
- Merck & Co Inc
- Genentech Inc
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
are the key Breast Cancer Therapeutics Market players profiled in the report.
Germany and Global Breast Cancer Therapeutics Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ XX Million |
| Market Size by 2030 | US$ XX Million |
| Global CAGR (2022 - 2030) | 9.5% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Drug Therapy
|
| Regions and Countries Covered | Germany
|
| Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Breast Cancer Therapeutics Market
- Eli Lilly and Co,
- Eisai Co Ltd
- Novartis AG
- AstraZeneca Plc
- Pfizer Inc
- Gilead Sciences Inc
- Merck & Co Inc
- Genentech Inc
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
Get Free Sample For